HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the pricing of a private placement of $1 billion aggregate principal amount of senior notes, comprised of $500 million aggregate principal amount of 3.000% senior notes due 2018 at an issue price of 99.874% and $500 million aggregate principal amount of 3.750% senior notes due 2020 at an issue price of 99.968%. Mylan intends to use the net proceeds from the offering to repay the amounts outstanding under its revolving credit facility and its accounts receivable securitization facility and to finance a portion of the repurchase of its ordinary shares pursuant to its previously announced share repurchase program. Subject to customary closing conditions, the sale of the notes is expected to close on or about December 9, 2015.
The notes will be sold only to qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act of 1933, and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. The proposed issuance of the notes will not be registered under the Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This press release contains forward-looking statements relating to the consummation of the offering described above and the anticipated use of proceeds therefrom. Consummation of the offering is subject to a number of conditions, some of which are beyond Mylan's control. Therefore, no assurance can be given that the offering will be consummated on the terms described or at all, or that the proceeds will be able to be deployed as indicated.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 30,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
SOURCE Mylan N.V.